SYNC-T Platform

About Syncromune

Syncromune is pioneering a first-in-class, in situ immunotherapy platform, SYNC-T, which combines partial oncolysis of a tumor with local infusion of a proprietary multi-target biologic drug. This approach aims to overcome the limitations of systemic immunotherapies by simultaneously addressing multiple immune suppression mechanisms while minimizing systemic toxicity. The company is advancing its lead candidate for mCRPC in the Phase 2 LEGION-100 trial and plans to expand into other metastatic solid tumors like non-small cell lung cancer and breast cancer. Founded in 2020, it is a private, pre-revenue company based in Boca Raton, Florida.

About Syncromune

Syncromune is pioneering a first-in-class, in situ immunotherapy platform, SYNC-T, which combines partial oncolysis of a tumor with local infusion of a proprietary multi-target biologic drug. This approach aims to overcome the limitations of systemic immunotherapies by simultaneously addressing multiple immune suppression mechanisms while minimizing systemic toxicity. The company is advancing its lead candidate for mCRPC in the Phase 2 LEGION-100 trial and plans to expand into other metastatic solid tumors like non-small cell lung cancer and breast cancer. Founded in 2020, it is a private, pre-revenue company based in Boca Raton, Florida.

Therapeutic Areas